Samsung Bioepis announces one-year results from Phase 3 study of SB11, a proposed biosimilar to Lucentis® (ranibizumab), at the American Academy of Ophthalmology (AAO) 2020 Virtual

Press/Media: Press / Media

Period	2020 Nov 16

Media coverage

Title	Samsung Bioepis announces one-year results from Phase 3 study of SB11, a proposed biosimilar to Lucentis® (ranibizumab), at the American Academy of Ophthalmology (AAO) 2020 Virtual
Media name/outlet	PipelineReview
Country/Territory	Spain
Date	20/11/16
URL	https://pipelinereview.com/index.php/2020111676554/Antibodies/Samsung-Bioepis-announces-one-year-results-from-Phase-3-study-of-SB11-a-proposed-biosimilar-to-Lucentis-ranibizumab-at-the-American-Academy-of-Ophthalmology-AAO-2020-Virtual.html
Persons	Kyunghwan Kim